- Home
- NOMD vs EYPT Comparison
NOMD vs EYPT Comparison
Compare NOMD & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NOMD | EYPT |
|---|---|---|
| Founded | 2014 | 1987 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Staples | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2015 | 2005 |
Fundamental Metrics
Financial Performance| Metric | NOMD | EYPT |
|---|---|---|
| Price | $10.35 | $14.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $14.25 | ★ $31.80 |
| AVG Volume (30 Days) | ★ 1.7M | 1.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 6.69% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.36 | $965.51 |
| P/E Ratio | $8.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.82 | $3.91 |
| 52 Week High | $20.22 | $19.11 |
Technical Indicators
Market Signals| Indicator | NOMD | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 26.20 | 44.35 |
| Support Level | N/A | $14.06 |
| Resistance Level | $12.36 | $18.99 |
| Average True Range (ATR) | 0.35 | 1.21 |
| MACD | -0.18 | -0.20 |
| Stochastic Oscillator | 15.80 | 15.31 |
Price Performance
Historical ComparisonAbout NOMD Nomad Foods Limited
Nomad Foods Ltd is a packaged foods company that is involved in the business of manufacturing and distribution of branded frozen foods in Western Europe. The company manufactures and markets frozen food products such as fish, vegetables, poultry, Ice Cream and ready meals like pizza. It sells its products through large grocery retailers under the brand Birds Eye in the United Kingdom and Ireland, Findus in Italy, France, Spain, and Scandinavia, and Iglo in Germany and other continental markets. The company operates through a single segment being Frozen. The majority of the revenue is generated from the United Kingdom.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.